MapLight Therapeutics (MPLT) Research & Development (2024 - 2026)
MapLight Therapeutics (MPLT) posted Research & Development of $64.6 million for Q4 2025, up 138.51% sequentially from $27.1 million in Q3 2025, and up 211.99% YoY from $20.7 million in Q4 2024.
MapLight Therapeutics (MPLT) Research & Development (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported Research & Development for 2 years, with the latest figure at $64.6 million in Q4 2025.
- Quarterly Research & Development rose 211.99% year-over-year to $64.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $129.2 million (changed N/A YoY) and the FY2025 annual result came in at $138.3 million, up 101.9% from the prior year.
- Research & Development advanced to $64.6 million in Q4 2025 per MPLT's latest filing, from $27.1 million in the prior quarter.
- Over five years, Research & Development peaked at $64.6 million in Q4 2025 and troughed at $16.8 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - | 53.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.44 Mn |
| Dec 31, 2025 | 64.62 Mn |
| Sep 30, 2025 | 27.09 Mn |
| Dec 31, 2024 | 20.71 Mn |
| Sep 30, 2024 | 16.81 Mn |